北京商报讯(记者丁宁)5月20日早间,三生国建(688336)发布公告称,公司及公司的关联方三生制药和沈阳三生制药有限责任公司(以下简称“沈阳三生”)共同授予被许可方辉瑞公司(Pfizer Inc.)(以下简称“辉瑞”)在许可区域(即除中国大陆以外的其他国家和地区)及领域(即人类和兽医用途的所有治疗、诊断及预防适应症)的独家开发、生产和商业化许可产品707项目(即同时靶向PD-1和VEGF的双...
Source Link北京商报讯(记者丁宁)5月20日早间,三生国建(688336)发布公告称,公司及公司的关联方三生制药和沈阳三生制药有限责任公司(以下简称“沈阳三生”)共同授予被许可方辉瑞公司(Pfizer Inc.)(以下简称“辉瑞”)在许可区域(即除中国大陆以外的其他国家和地区)及领域(即人类和兽医用途的所有治疗、诊断及预防适应症)的独家开发、生产和商业化许可产品707项目(即同时靶向PD-1和VEGF的双...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.